TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05683977
Drug: durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
Study: NCT05038111
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: perioperative dexmedetomidine infusion
Study: NCT04455958
Drug: Lopinavir/Ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06771128
Drug: Ginkgo Biloba oral tablet
Normalized name: ginkgo biloba ORAL TABLET
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive Ginkgo Biloba oral tablet 120 mg once daily
Study: NCT06771128
Drug: Desmopressin Acetate 0.2 mg Tablets
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient receives desmopressin 0.2 mg oral tablet once daily
Study: NCT03770663
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
Study: NCT06641154
Drug: GT-UGT1A1-AAV8-02
Normalized name: AAV8-RPGR
DrugBank: Cotoretigene toliparvovec (DB16797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, single dose
Study: NCT06195072
Drug: Amlitelimab
Normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP will be administered subcutaneously by the Investigator or designee as follows:~* Amlitelimab or~* Matching placebo
Study: NCT06195072
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will take the active investigational product BI 1015550 or matching placebo provided as film-coated tablets, administered orally BID.
Study: NCT06582706
Drug: Extended Release Niacin
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg
Study: NCT04680273
Drug: GDC-9545 Solution for Infusion
Normalized name: GDC-0425
DrugBank: GDC-0425 (DB14791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
Study: NCT06157242
Drug: Xeruborbactam Oral Prodrug
Normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Fostroxacitabine bralpamide (DB18090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT06157242
Drug: Ceftibuten
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental
Study: NCT06704633
Drug: Sacubitril / Valsartan Oral Tablet
Normalized name: sacubitril / valsartan Oral Tablet
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A 36-hour wash-out of ACE inhibitors before initiating ARNI will be done, because of a risk of angioedema if ARNI is started without a wash-out period. The ACE inhibitor or ARB will be switched to sacubitril/valsartan 50mg twice daily (24.3 mg sacubitril, 25.7mg valsartan) for two weeks, increased to 100mg twice daily for three weeks, followed by 200mg twice daily
Study: NCT06797973
Drug: Intrathecal Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 μg preservative-free morphine (0.2 ml) added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl
Study: NCT06797973
Drug: Placebo (Sodium Chloride Injection, 0.9%)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2 ml of isotonic sodium chloride added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl.
Study: NCT05899127
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5mg/kg induction，1.5 mg/kg/h maintenance
Study: NCT05899127
Drug: 0.9%NaCl
Normalized name: triamcinolone acet/0.9%NaCl/PF 40 mg/mL INJECTION VIAL (ML)
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg/kg induction，1.5 mg/kg/h maintenance
Study: NCT05704829
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DXd i.v.
Study: NCT04882735
Drug: Acoramidis
Normalized name: Acoramidis
DrugBank: Acoramidis (DB17999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTR stabilizer administered orally twice daily (BID)
Study: NCT05621070
Drug: JS002
Normalized name: Immunoglobulin g4, anti-(neural apoptosis-regulated convertase 1) (human monoclonal js002 .gamma.4-chain), disulfide with human monoclonal js002 .kappa.-chain, dimer
DrugBank: Ongericimab (DB18949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.
Study: NCT05621070
Drug: JS002
Normalized name: Immunoglobulin g4, anti-(neural apoptosis-regulated convertase 1) (human monoclonal js002 .gamma.4-chain), disulfide with human monoclonal js002 .kappa.-chain, dimer
DrugBank: Ongericimab (DB18949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.
Study: NCT05620628
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab will be administered at 1500mg every 4 weeks from cycles 1 day 1.
Study: NCT05620628
Drug: Savolitinib
Normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savoritinib 600mg will be administered orally a day for 28 days as one cycle.
Study: NCT05156047
Drug: Open-label pitolisant
DrugBank: Pitolisant (DB11642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.
Study: NCT05156047
Drug: Double-blind pitolisant
DrugBank: Pitolisant (DB11642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.
Study: NCT05278663
Drug: E6742
Normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E6742 tablet.
Study: NCT04463771
Drug: retifanlimab
Normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
Study: NCT04463771
Drug: epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epacadostat will be administered orally BID.
Study: NCT04463771
Drug: pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pemigatinib will be administered orally QD.
Study: NCT04463771
Drug: INCAGN02385
Normalized name: Anti-LAG-3 Monoclonal Antibody INCAGN02385
DrugBank: Tuparstobart (DB19118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCAGN2385 will be administered every 2 weeks
Study: NCT04463771
Drug: INCAGN02390
Normalized name: INCAGN02390
DrugBank: Verzistobart (DB18895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCAGN2390 will be administered every 2 weeks
Study: NCT06473844
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10mg once daily from recruitment to hospital discharge
Study: NCT06453824
Drug: MDI-2517
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: study drug
Study: NCT04939844
Drug: Isatuximab, bortezomib, lenalidomide, dexamethason
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All participants will receive the same treatment as described under arm.
Study: NCT06424756
Drug: Tempol
Normalized name: Tempol
DrugBank: Tempol (DB12449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
Study: NCT06424756
Drug: L-NAME
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.
Study: NCT06424756
Drug: SNP - Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At the end of each experimental visit, SNP will be perfused through microdialysis fibers to elicit a maximal vasodilation response.
Study: NCT05504226
Drug: Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
Normalized name: Teneligliptin (as teneligliptin hydrobromide) 20 mg oral tablet
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: To be orally administered once daily for 52 weeks.
Study: NCT05504226
Drug: Teneligliptin Placebo Oral Tablet
Normalized name: placebo Oral Tablet
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: To be orally administered once daily for 52 weeks. This arm will be switched to teneligliptin from week 24.
Study: NCT06786208
Drug: Sunvozertinib
Normalized name: Sunvozertinib
DrugBank: Sunvozertinib (DB18925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sunvozertinb, a EGFR-TKI, 300mg QD oral
Study: NCT05959239
Drug: TB006
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TB006 will be provided as single-use injectable glass vials.
Study: NCT05113966
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-use, sterile powder to be reconstituted and further diluted with 250 milliliters (mL) of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
Study: NCT05113966
Drug: Sacituzumab Govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 milligram per kilogram (mg/kg) reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
Study: NCT04561206
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04868760
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
Study: NCT00002022
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05657301
Drug: KH631
Normalized name: Ketamine hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KH631: AAV vector containing a coding sequence for an anti-VEGF protein
Study: NCT05406674
Drug: Cisplatin 100 mg/m2
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 milligram(s)/square meter
Study: NCT05406674
Drug: Cisplatin 40 mg/l
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/I milligram(s)/litre
Study: NCT06379659
Drug: Growh hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this group, patients will receive growth hormone solution containing 1.99 milligrams of the drug dissolved in 1.5 milliliters of 0.9% saline solution (normal saline), in addition to standard hormonal therapy, starting from cycle day 10. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, growth hormone infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
Study: NCT06787586
Drug: ATTO-1310
Normalized name: ADALIMUMAB-ATTO
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ATTO-1310 Attobody
Study: NCT06790745
Drug: Plasma rich fibrin epidural injection by Racz catheter
Normalized name: plasma protein fraction Injection
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive plasma rich fibrin injection by Racz catheter
Study: NCT05147194
Drug: Trimetazidine
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral，35mg bid
Study: NCT04662112
Drug: NASOX
Normalized name: SODIUM CHLORIDE 1.2 mg in 10 mL NASAL SPRAY [NasoxinSpray]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxalipatin 60 mg/m2 IV (2 h infusion) on Day 1, every 2 weeks Nal-IRI 50-60 mg/m2 IV (FBE, 90 min infusion) on Day 1, every 2 weeks S-1 40mg/m2 oral twice daily on Day 1-7, every 2 weeks
Study: NCT05442554
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin IV infusion.
Study: NCT05854966
Drug: CPI 613
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only.~For MAINTENANCE therapy (21 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 21-day cycles until progression, intolerable toxicity or withdrawal of consent.
Study: NCT05854966
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For INDUCTION therapy (14 day cycles):~Metformin 500 mg daily (taken with meals), days 1-2 for cycle 1 only. Metformin 500 mg twice daily (taken with meals), days 3-14 for cycle 1 only. Metformin 1,000 mg daily (taken with meals), days 1-2 for cycle 2 only. Metformin 1,000 mg twice daily (taken with meals) days 3-4 for cycle 2 only.~For MAINTENANCE therapy (21 day cycles): Metformin 1,000 mg twice daily (taken with meals) days 1-21 until progression, intolerable toxicity or withdrawal of consent
Study: NCT04769479
Drug: acoramidis
Normalized name: Acoramidis
DrugBank: Acoramidis (DB17999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acoramidis
Study: NCT05314621
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Flonase® Allergy Relief (nasal spray)
Study: NCT05314621
Drug: Tears Naturale
Normalized name: Tears Naturale
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tears Naturale® II (eye drop)
Study: NCT05534594
Drug: 18F-PSMA-1007
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As explained under 'Arms'.
Study: NCT05415137
Drug: Efzofitimod 3 mg/kg
DrugBank: Efzofitimod (DB16453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EfzofitimodIV infusion every 4 weeks for a total of 12 doses
Study: NCT05415137
Drug: Efzofitimod 5 mg/kg
DrugBank: Efzofitimod (DB16453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EfzofitimodIV infusion every 4 weeks for a total of 12 doses
Study: NCT06780839
Drug: Ensartinib
Normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Ensartinib 225mg QD by MRD test guided, if MRD test shows negative, only ensartinib will be given. if MRD test turns from negative to posive, patients will receive step-up treatment, which is ensartibe plus platinum - based doublet chemotherapy no more than 4 cycles. If MRD test turns from posive to negative, only ensartinib will be given. if MRD test constantly shows positive, MDT will determine the next step ensartib-based therapy.
Study: NCT04996160
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT04996160
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg/m2/day divided BID, PO, NG, or IV
Study: NCT04996160
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/m2/dose, IV (preferred) or SC
Study: NCT06720415
Drug: Oral methadone, immediately prior to transport
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 0.4mg/kg PO methadone immediately prior to transport to the operating room
Study: NCT06720415
Drug: Intravenous methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 0.3mg/kg IV methadone after induction of general anesthesia
Study: NCT05281484
Drug: CNM-Au8
Normalized name: CNM-Au8
DrugBank: CNM-Au8 (DB17952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids).~Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm).
Study: NCT05188508
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.
Study: NCT05276063
Drug: Linsitinib
Normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication taken twice daily by mouth
Study: NCT05663710
Drug: 177Lu girentuximab
Normalized name: Brentuximab Vedotin
DrugBank: Girentuximab (DB05304)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT05663710
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT05663710
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO
Study: NCT05101317
Drug: HMI-115
Normalized name: HMI-103
DrugBank: HMI-103 (DB17684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMI-115 is human monoclonal antibody
Study: NCT06512584
Drug: PJ009
Normalized name: Pralsetinib
DrugBank: Pralsetinib (DB15822)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subcutaneous injections, 0.05 mg/kg once daily
Study: NCT06358573
Drug: INT230-6
Normalized name: INT230-6 COMPONENT CISPLATIN
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate.~The IMP is without marketing authorization in Switzerland and anywhere in the world.
Study: NCT04761302
Drug: Intravenous morphine and oral oxycodone
Normalized name: oxycodone and ibuprofen
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.
Study: NCT05765344
Drug: Bulevirtide
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Administered via subcutaneous injections.
Study: NCT06305416
Drug: Ranibizumab 10mg/ml Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab 10mg/ml Injection (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
Study: NCT06305416
Drug: Lucentis
Normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
Study: NCT05814107
Drug: CT-996
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule of CT-996
Study: NCT04709380
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib is a multi-targeted oral drug for the treatment of cancer.Treatment of inoperable advanced renal cell carcinoma ,inoperable or distant metastatic primary hepatocellular carcinoma and so on.
Study: NCT05653258
Drug: Dasatinib 100 MG
Normalized name: dasatinib 100 MG
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg of dasatinib (D) daily for 3 consecutive days plus quercetin (Q) for the same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
Study: NCT05653258
Drug: Quercetin 1000mg
DrugBank: Quercetin (DB04216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (Q) (4) 250 mg capsules daily (total 1000 mg daily) plus dasatinib (D) same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
Study: NCT06126380
Drug: AT-1501
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent